2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults
Clinical Infectious Diseases·
- DOI
- 10.1093/cid/ciaf680
- PMID
- 41920902
- PMCID
- —
- OpenAlex
- W7147127129
- Study type
- Guideline
- Publisher
- Oxford University Press (OUP)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The article provides an evidence-based framework for selecting antiviral treatments for adults with mild to moderate COVID-19. The supplied abstract does not report population-level outcomes or surveillance findings.
Structured evidence summary
Research question
The article updates recommendations on antiviral treatment and management for adults with mild to moderate COVID-19, focusing on nirmatrelvir/ritonavir, remdesivir, and molnupiravir.
Study design
This is a clinical practice guideline update developed by an Infectious Diseases Society of America panel. Its recommendations draw on a systematic literature review and use the GRADE framework to rate evidence certainty and recommendation strength.
Population and setting
The recommendations address adults with mild to moderate COVID-19. The supplied evidence does not specify individual study locations or healthcare settings.
Main findings
The panel provides nine updated recommendations concerning nirmatrelvir/ritonavir, remdesivir, and molnupiravir. It also includes guidance on applying the recommendations and an antiviral-selection algorithm.
Public-health relevance
The article provides an evidence-based framework for selecting antiviral treatments for adults with mild to moderate COVID-19. The supplied abstract does not report population-level outcomes or surveillance findings.
Important limitations
The supplied evidence does not state specific guideline limitations. This summary relies only on the single supplied article abstract and metadata; the original paper is required for decision-grade interpretation of the evidence, recommendation conditions, and applicability.
GIDS interpretation
The article is discoverable in contexts concerning COVID-19 treatment and health policy because it is classified under those topics and addresses antiviral recommendations. It provides clinical-guideline context only and does not establish or confirm a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 10 auditable classifier relationships to diseases, places, topics, and study design.